You are here

Rheumatoid Arthritis and Psoriasis Trials for Vitaxin Halted

GAITHERSBURG, Md., Aug. 30 /PRNewswire-FirstCall/ -- MedImmune, Inc. (Nasdaq: MEDI) announced today that it has decided to terminate Phase 2 testing of Vitaxin(R) in patients with rheumatoid arthritis (RA) and psoriasis based on preliminary data suggesting lack of clinical benefit in these inflammatory diseases. There were no safety concerns identified in the preliminary analyses. MedImmune's oncology program for Vitaxin continues to advance with studies in melanoma and prostate cancer.

About Vitaxin
Vitaxin targets the alpha-v beta-3 integrin, which is a protein expressed on the surface of newly forming blood vessels, certain tumor types and on a number of other cell types, including macrophages and osteoclasts. Based on preclinical models, the alpha-v beta-3 integrin has been implicated in a number of disease processes, including the growth and metastasis of tumors, the bone destruction in RA and the inflammatory process in psoriasis.

Source: MedImmune, Inc.

Recent Headlines

Patients Had Improved Lung Function, Fewer Exacerbations
Particularly Serious: Antidepressants, Drugs for Parkinson’s and Epilepsy
Drug “Remarkably Effective” at Killing Range of Gram-Positive Bacteria
Up to 70% Greater Risk of Bacterial Infection, 48% Risk for Fungal Infection
Record-High Number of Cases in France, Italy, Greece, Other Locations
Will Have a Longer Shelf Life Than Current, Expired Stockpile
Most Women Undergoing Surgery for Suspected Cancer Do Not Have It
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy